Print Page   |   Contact Us   |   Report Abuse   |   Sign In   |   Register
Community Search
News & Press: Industry News

Amgen loss 'a temporary blip' for Seattle biotech: Man behind Arch Venture's $400M fund speaks out

Wednesday, August 27, 2014   (0 Comments)
Posted by: Megan Jeffrey
Share |
Amgen loss 'a temporary blip' for Seattle biotech: Man behind Arch Venture's $400M fund speaks out | Puget Sound Business Journal 

more WBBA Calendar

12/3/2014
Got Investigational New Drug Questions? Secrets to Successful INDs & Virtual Development Teams

1/11/2015
J.P. Morgan- Washington Reception

Featured Partners
Business WireOn behalf of thousands of company and organizational clients, Business Wire transmits full-text news

Membership Management Software Powered by YourMembership.com®  ::  Legal